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                  ABSTRACT  
 
Objectives: A new dosimetric variable, dose dropping speed (DDS), was proposed and used to 
evaluate normal tissue sparing among stereotactic radiosurgery (SRS) plans with different 
prescription isodose lines.  
Methods: Forty plans were generated for 8 intracranial SRS cases,  prescribing to isodose levels 
(IDLs) ranging from 50% to 90% in 10% increments. Whilst maintaining similar coverage and 
conformity, plans at different IDLs were evaluated in terms of normal tissue sparing using the 
proposed DDS.  The DDS was defined as the greater decay coefficient in a double exponential 
decay fit of the dose drop-off outside the PTV, which models the steep portion of the drop-off. 
Provided that the prescription dose covers the whole PTV, a greater DDS indicates better normal 
tissue sparing. 
Results: Among all plans, the DDS was found the lowest for the prescription at 90% IDL and 
the highest for the prescription at 60% or 70%. Beam profile slope change in penumbra and its 
field size dependence were explored and given as the physical basis of the findings. 
Conclusions:  A variable was proposed for SRS plan quality evaluation. Using this measure, 
prescriptions at 60% and 70% IDLs were found to provide best normal tissue sparing.  
Advances in knowledge: A new variable was proposed based on which normal tissue sparing 
was quantitatively evaluated, comparing different prescription IDLs in SRS. 
 
Keywords: Prescription isodose, dose drop-off, stereotactic radiosurgery. 
Short title:  SRS plan normal tissue quality evaluation 
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I. INTRODUCTION 
      Stereotactic radiosurgery (SRS) has gained increasing popularity as a treatment modality for 
patients with brain metastases as well as other malignant and benign brain lesions.
1
 SRS has 
traditionally been performed by using an invasive fixed head frame that establishes the 
stereotactic coordinates of the target.
2
 More recently, frameless stereotactic systems have been 
developed and implemented with the help of an image-guided system.
3-11
 
      The reports of radiation therapy oncology (RTOG reports
12-15
) have made specific 
prescription dose recommendations for brain SRS treatments based on different target volumes. 
But the prescription isodose level (IDL) can vary from 50% to 90% among different clinical 
practices. Therefore, it is interesting to find out which prescription IDL would be most suitable 
for brain SRS. In fact, a recent study has been conducted in this aspect
16
. In Ohtakara et al’s 
study [16] 10 SRS cases have been retrospectively planned and studied comparing different IDLs 
(90%, 80%, and 70%), and the authors have found the best prescription IDL at 70% for those 10 
cases, based on . The technique used in their study was non-coplanar dynamic conformal 
arcs, standard in brain SRS treatments. However, in the study, no physical reason was explored 
to explain the findings, and the studied prescription IDLs ranged from 70% to 90%, rendering it 
inadequate to determine if 70% was truly the extrema. Whilst we explored a similar topic in this 
paper, we used a broader search range of 50%-90%, the range of clinically used prescription 
IDLs, to comprehensively study the normal tissue dose effect of prescription IDLs. Furthermore, 
we proposed in this work a new and useful variable, dose dropping speed (DDS) which reflects 
the radial dose drop-off from the PTV surface, defined as the greater decay coefficient in a 
double exponential decay fit of the dose drop-off outside the PTV, to quantitatively evaluate the 
normal tissue sparing. The double exponential decay fit takes a global look at the dose drop-off 
%50V
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outside the PTV, with the greater decay coefficient characterising the steep portion of the drop-
off or the higher dose gradient region, and the lesser decay coefficient characterising the shallow 
portion or the lower dose gradient region. Our work chose to define the greater decay coefficient, 
due to its greater clinical relevance, as a quantitative measure called DDS, and used it in our 
investigation of normal tissue dose effect of prescription IDLs. In addition to discovering the 
effects of the prescription IDLs on the plan quality, our work also explored the physical aspects 
in the attempt to explain the observations. The normal tissue sparing trend of different 
prescription IDLs was found to result from the different gradients of the penumbra on the 
LINAC beam profile of the corresponding effective field size. Effectively speaking, a different 
part of the beam penumbra of a different beam field size is used to surround the PTV on the plan 
of a given prescription IDL. Moreover, our work also uncovered a target size dependence of the 
observed normal tissue dose trend and explored its physical basis. Finally, the planning 
technique had also some difference from Ohtakara et al’s work. In their study, block margin was 
only uniformly adjusted for plans with different prescription IDLs, whilst in our study, we 
manually optimised individual MLC leaf positions for each plan to generate realistic plans with 
quality satisfactory to our clinical standards.  As a result, in our work the plans with different 
IDLs for the same patient all had high and matched coverage and conformity, therefore rendering 
our results and conclusions more generalizable to clinical SRS practice. 
       It is difficult to simply define what a good plan entails. But in general, a good plan shall 
have both good local control and at the same time good normal tissue sparing to the extent 
possible, and this is especially true for SRS cases in which an ablative dose is given in a single 
fraction. In other words, hot spots in the PTV may be tolerated but the normal tissue shall be as 
cold as possible. As will be shown in this paper, the prescription IDLs were revealed to affect the 
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normal tissue sparing in an SRS plan. Normal tissue sparing is usually quantitatively or 
qualitatively evaluated in a variety of ways. One way is to assess specific dose-volume endpoints 
for different organs at risk (OARs), such as the maximum dose to the brainstem, or the volume 
of normal brain tissue getting over 12 Gy. These endpoints are useful because they are often 
linked with specific found toxicities and therefore represent what the clinicians are most 
interested in to constrain the dose and minimise the toxicities. On the other hand, each of these 
measures only represents a local and partial view of the entire plan. As a result, those variables 
cannot be used to represent the general dose change trends inside the normal tissue. Another 
popular way to evaluate normal tissue dose is to use %50V  as has been done in the study of 
Ohtakara et al [16]. However, %50V has the same shortcoming as the dose volume histogram that 
it does not reflect the “coordinate information”. In other words, for the same %50V  the dose can 
be distributed in many different positions. Furthermore, %50V only studies the dose effect at a 
localised dose level, i.e. 50%. Finally, the selection of %50V not %55V   or %40V is arbitrary. Thus 
there is a natural question whether we could find a generic function which can be used to 
describe the dose distribution outside the PTV. In this work, we have proposed a double 
exponential function for this purpose.  In this work we proposed a new parameter named DDS, 
extracted from a global fitting of the dose drop-off outside the PTV, to quantitatively and 
comprehensively evaluate normal tissue sparing, and study the effects of different prescription 
IDLs in brain SRS.  
      Our dose drop-off calculation involves some position information of the dose distribution 
which is ignored in the above-enumerated measures, and thus provides us information which can 
be used to evaluate the general dose trends outside the PTV. The DDS as we defined using the 
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greater decay coefficient in a double exponential decay fit of the dose drop-off outside the PTV 
is of course an interesting measure which has not been explored in the existing literatures. 
      The goals of SRS are the ablation of target tissue and the sparing of critical normal tissue. 
Largely due to the little normal tissue usually contained in an SRS PTV, dose inhomogeneity 
inside the PTV is considered acceptable. Conventionally, the “sphere-packing” type of SRS, 
such as Gamma Knife, prescribes to a fairly low IDL, usually around 50%, whilst such low 
prescription IDL would not be used for radiotherapy with conventional fractionations in which 
target uniformity is critical. High prescription IDLs such as 90% are achievable in LINAC-based 
SRS, although a broad range of IDLs from 50% to 90% have been used in clinical practice due to 
the relative freedom from the target uniformity restriction and the importance of normal tissue 
sparing outside the PTV. Whilst our work was conducted based on our proposed DDS to study 
the normal tissue dose effect and identify the prescription IDL that would provide the optimal 
normal tissue sparing outside the PTV, there are a few other items need to be taken into 
consideration. Most important of all, the tolerance of target dose heterogeneity is still clinically 
important even for SRS. Although usually within the target itself, the hottest dose point in a low 
prescription IDL plan can have much higher dose than that in a high prescription IDL plan. For 
example, for a plan with 18 Gy prescribed to 90% IDL, the hottest dose is around 20 Gy whilst 
another plan with the same dose prescribed to 50% IDL will have the hottest dose at around 36 
Gy. Because single fraction SRS treatment was found to cause necrosis sometimes
17-20
, very high 
dose points shall still be avoided and therefore plans with very low prescription IDLs may not be 
clinically practical or appropriate. In addition, because plans with lower prescription IDLs 
deliver higher maximum doses and require larger numbers of monitor units, they may in turn 
result in larger integral dose and may cause logistic problems such as longer irradiation time.  
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Last but not the least, a plan with a lower prescription IDL has a smaller effective field size than 
a plan with a higher IDL. Because the typical smallest multi-leaf collimator (MLC) field size 
commissioned for LINAC-based SRS is about 1 cm, the smaller effective field size in low IDL 
plans for a very small target may lead to bigger dosimetric errors than a larger field size in high 
IDL plans would.  
      Here we report our work in which we used the DDS calculated from a double exponential 
decay function fit of dose drop-off outside the PTV to investigate normal tissue sparing on brain 
SRS plans with 50%-90% prescription IDLs. A total of 40 plans were retrospectively generated 
for 8 brain SRS patients who had been clinically treated with 90% IDL plans. The physical basis 
of the observed phenomena will also be discussed.  
 
 II. METHODS  
      Under a study approved by the Institutional Review Board, eight previously treated brain 
SRS patients were randomly selected, including one acoustic neuroma, one meningioma, two 
pituitary lesion, and four metastatic tumors. Table 1 lists the disease sites, locations, and the PTV 
volumes for all the patients. These patients were clinically treated prescribing to 90% IDL 
following the practice guideline at our institution. In our work, a single physicist first re-planned 
the 8 cases at 90% IDL with non-coplanar 6 MV dynamic conformal arcs using iPlan (BrainLab 
AG, Feldkirchen, Germany) for a Novalis machine (BrainLab AG,   Feldkirchen, Germany). 
Subsequently, whilst fixing the arc number and orientation for each patient, the physicist 
manually optimised the individual microMLC leaf positions to create plans with the other 
prescription IDLs (80%, 70%, 60%, and 50%).  The plans were created such that the PTV 
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coverage and conformity were similar for the same patient on the different plans. The typical 
number of arcs was around five.   
      To quantitatively evaluate the dosimetric effect on the normal tissue for individual plans, we 
proposed to use a new metric, the DDS, defined as the following. Firstly, one-mm-thick 
concentric rind structures were generated layer by layer from immediately outside the PTV to 
when the rind structure reaches the head surface (see an example patient image in Fig. 1). 
Secondly, the average dose inside each rind structure was calculated. Thirdly, an analytical 
double exponential decay function was fitted to describe the average dose as a function of the 
distance from the PTV surface, as in Eq. (1). 
               (1) 
   
where D(r) [Gy] denotes the average dose in a rind structure with the distance of r [mm] from the 
PTV surface. The two terms are symmetrical in the Eq. (1). The steeper decay is always denoted 
as the first exponential term , and the shallower decay as the second exponential 
term . Lastly, we defined b1, the greater decay coefficient from the steeper decay of 
the fit, as our proposed variable DDS.  When , which corresponds to the surface 
immediately outside the PTV, the second term of Eq. (1) approaches a constant value. Therefore, 
the first exponential dominates the dose drop-off in the areas outside but close to the PTV, i.e., 
the medium-to-high dose region outside the PTV. On the other hand, at a point farther away from 
the PTV surface, the contribution of the first term becomes less prominent.  For example, at a 
point with the distance of mm from the PTV surface, the contribution of the first term is . 
)exp()exp()( 2211 rbarbarD 
)exp( 11 rba 
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At a point with the distance of  mm, the contribution of the first term becomes . It is 
obvious that at   , the two terms in Eq. (1) are equal. At a point closer than , 
the first term dominates the contribution, and on the other hand, at a point farther away than , 
the second term dominates. We defined b1 to be our proposed variable DDS, because the dose 
drop-off in the normal tissue immediately outside and close to the PTV is always of the most 
clinical importance in brain SRS.   
      Suppose a plan is made perfectly such that the prescription IDL completely covers and 
perfectly conforms to the surface of the PTV, a larger DDS is then preferable because it means 
faster dose drop-off immediately outside and close to the PTV. The OARs close to the PTV will 
receive lower dose. On the other hand, a smaller DDS indicates slower dose drop-off leading to a 
higher dose to the OARs close to the PTV.    
       For the 40 plans we generated for the 8 SRS patients (5 plans with prescription IDLs set at 
50%-90% for each patient), we calculated the dose distribution outside the PTV and applied the 
above described fitting to it for each plan to investigate the normal tissue dose effect of different 
prescription IDLs. To explore the physical basis behind the studied effect and its trend, the 
MLC-collimated square field beam profiles measured at the commissioning and modeled by the 
treatment planning system were inspected in connection with the clinical plans.  
      To explore the target size dependence we conducted a simulated phantom study in which a 
hypothetical spherical target was used for brain SRS. In the study we fixed the prescription IDL 
at 80% and changed the spherical target diameter from 4.90, 4.05, 3.20, 2.30, to 1.2 cm.  A plan 
was generated for each target size, from which the DDS for each target size was calculated. 
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III. RESULTS 
      In Fig.2, one example of the dose as a function of the distance from the PTV surface is 
shown (Patient 4 in Table 1). In this figure, the prescription IDL is 80%.  Using Equation (1) to 
fit it, the fitted coefficients were  
 mmbGya
mmbGya
/10054.004234.0),(617.0218.4
),/1(013.02477.0),(57.043.18
22
11


 
      For this plan, the halfway dose decay distance for the DDS was . The halfway 
dose decay distance for the second exponential term was .  At , the 
contributions from the two terms were equal. 
     Comparing the 5 different prescription IDL plans for each patient, similar trends were found 
for all 8 patients. The isodose distributions outside the PTV for one example patient are given in 
Fig.3 for cases of prescription IDLs from 90% to 50% (Patient 2 in Table 1). From the figure the 
following two observations were made: (1) It appeared that for the plans with all other 
prescription IDLs the high dose distribution more tightly hugs the PTV than the 90% plan. (2) 
For the lower prescription IDL cases (i.e. 50%) the lower dose was more spread out. The average 
dose in each rind structure as a function of the distance from the PTV surface is plotted for each 
plan in Fig. 4 for this example patient (Patient 2). It was clear that for the 90% prescription IDL 
plan, the dose drop-off in the medium-to-high dose region was the slowest. On the other hand, 
the tissue dose at the largest studied distance from the PTV was the highest for the 50% 
prescription IDL plan. These findings were in accordance with the observations from Fig. 3.  
       To quantify the observations from Fig.4, Eq. (1) was used to fit the dose distribution and the 
results are provided in Table 2. The conformity index, defined as the ratio of the prescription 
mm
b
8.2
2ln
1

cm
b
6.1
2ln
2
 mmr 2.70 
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dose covered volume to the PTV volume, is also given in Table 2 for all plans. It was clear that 
similar conformity was achieved across different prescription plans for the patient.  Because the 
first rind in the data extraction was so close to the PTV (1mm from the surface of the PTV) that 
its average dose was often more affected by the minute differences in plan conformity, we chose 
to exclude this point from the fitting, which led to the fitted coefficients shown in row 2 to row 5. 
The total MUs for all plans are also provided in Table 2. It is interesting to note that the DDS 
was found optimal (the highest) in the 70% plan. For other patients not shown, the DDS was 
found optimal either in the 70% or the 60% plan. The exact optimal percentage IDL may depend 
on the PTV volume, location, and other factors, though all 8 patients showed a plateaued DDS 
peak at around 60-70%. The other observation is that for a lower IDL, the MU number is also 
increased and this is understandable. For a lower IDL, the maximum dose inside the PTV 
increases, thus the corresponding MU also increases. The numbers of MU of the plans with 
different IDLs are almost inverse proportional to the IDLs. For example, the MU ratio for the 
plans at 50% and 90% IDL is 1.838, which is almost the same as the inverse ratio of the two 
IDLs which is 1.8. We need to point out that in addition to the higher dose heterogeneity inside 
the PTV, the higher MU at the lower IDL may also lead to slightly broader low dose region, 
although our DDS study concentrates on the more clinically-relevant region of medium-to-high 
dose.   
      The DDS values of different prescription IDL plans of all eight patients are presented in 
Fig.5. From the plot, it is clear that the DDS was always the lowest in the 90% IDL plan and it 
increased with lower IDL plans until it plateaued at about 60-70% prescription IDLs. The ratio of 
the highest DDS to that in the 90% case was between 1.18 and 2.10. The mean ratio was 
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1.65±0.33 (one standard deviation).  An Anova analysis indicated that the DDS difference was 
significant between the optimal plans (60% or 70%) and the 90% plans with p<0.01. 
      In exploring the beam profiles, the observed DDS trend in the clinical cases was found to 
correlate with the beam profiles in the following ways. The beam aperture size or MLC block 
margin is different when we prescribe at the 90% IDL versus at 70% IDL. In general, the lower 
the prescription IDL, the smaller are the beam aperture sizes for the same case. To understand 
the observations of the effects of prescription IDL on the DDS, our investigation on the beam 
profiles for different field sizes are presented here. 
      Fig.6 plots the beam profiles for different MLC-defined square field sizes with varying sizes 
from 6 mm×6 mm to 52 mm×52 mm.  It is apparent that the beam profile became narrower and 
dropped faster around the penumbra region when the field size was smaller. To more clearly 
appreciate this, the absolute value of the gradient, calculated using the first-order derivative of 
the profiles, as a function of the distance from the central axis is plotted in Fig.7. It is interesting 
to note that the gradient was larger as the field size got smaller.  
      A target size dependence was found for the DDS from the simulated phantom study. The 
DDS of the 80% IDL plan was compared for a simulated spherical target of varying diameters.  
In Fig.8, the DDS as a function of the target diameter is plotted. It is clear that when the target 
became smaller, the DDS became larger.  
      A similar trend with varying target sizes was also seen for all but two patient cases.  Fig.9 
plots the optimal (maximum) DDS from all 5 plans with different prescription IDLs for each 
patient as a function of the corresponding PTV volume. Except Patient 7 and Patient 8 who had 
PTV volumes smaller than 1 cc, for the larger PTVs the DDS decreased as the PTV volume 
increased. This trend as seen in the 6 patients with larger PTVs and in the simulated target study 
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could be due to the similar volume (field size) dependence of the calculated slope of the beam 
profiles (using the first-order derivatives) as a function of percentage dose of the central axis 
(CAX) values as plotted in Fig.10.  For the two small PTVs that didn’t follow the trend, one was 
very close to the surface of the head (Patient 8) and the other was an acoustic neuroma sitting 
inside bony structures (Patient 7).  For the acoustic neuroma case, the target location was quite 
different from the others. Therefore, the DDS might have also depended on the target location 
and its distinct surrounding structures. For Patient 8 for whom the target was close to the surface 
of the head, in addition to the beam profile effects described above, the effects of the beam depth 
dose contribution shall also be considered. 
      The beam depth dose curves for different field sizes are given in Fig. 11. From this figure, 
one can also observe the field size dependence of the dose drop-off. The dose drop-off was faster 
when the field size was smaller. For example, we could use  
                                                                                              (2) 
to fit the PDD curve for the depth larger than the dmax, where x is the depth. It is interesting to 
observe that µ=0.006702(1/mm) at the field size of 6mm×6mm and µ=0.005935(1/mm) at the 
field size of 52mm×52mm. It was clear that the ratio was around 1.13. But the absolute values 
were about two orders of magnitude smaller than the DDS shown in Fig.8.  The absolute value of 
the gradient (i.e. the first-order derivative) as a function of the depth is given in Fig. 12 for 
different field sizes. It was clear that the gradient of PDD was almost zero at depths larger than 
1.5 cm for all field sizes. Thus the effect was negligible with a target deeper in the head.  For 
targets close to the surface of the head, this will affect the dose distribution, such as in the case of 
Patient 7.  Therefore, the general trend shall still hold: The DDS is larger for smaller targets or 
))(exp( max0 dxDD  
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lower prescription IDLs, when the target is at an effective depth from the head surface much 
larger than the dmax of the beam.  
 
IV. DISCUSSIONS 
      In our work a new variable DDS was proposed to evaluate the dose drop-off in the medium-
to-high dose region outside the PTV in brain SRS. The DDS was extracted from a double 
exponential decay fit of the relationship between the average dose in concentric shells outside the 
PTV and their distances from the PTV surface. Because in the double exponential decay fit the 
second term is much smaller than the first one by definition, one could also use the following 
function  
                                   (3) 
to fit the dose distribution outside the PTV.  In fact, as shown in Table 2, for the double 
exponential decay fit was usually much smaller than our defined DDS . In the single 
exponential function discussed here, a newly defined DDS alternative, ,  shall exhibit similar 
dependence on prescription IDL as in the double exponential decay fit. It should be noted that 
the absolute value of the DDS depends on the plan quality. But the discovered trend that the 
DDS increases as the prescription IDL decreases from 90% to the lower prescription IDLs seems 
to be independent of the specific plans as long as the plan quality are consistent with each other 
for plans with different prescription IDL. One small precaution we have exercised in the work to 
decrease the effects of small plan quality fluctuations was excluding the first data point 
immediately outside the PTV from the fitting, which was proven effective. Additionally, the 
DDS may also depend on the target location and its surrounding structures, effects that were 
touched on but were not studied extensively in this paper. These effects are not expected to 
2b 1b
3b
1b
c r b a r D    ) exp( ) ( 3 3 
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change the discovered DDS vs. prescription IDL relationship demonstrated in Fig. 5. The reason 
is that the relationship is closely related to the gradients of beam profiles of different field sizes 
as plotted in Fig. 10.  
      In understanding the normal tissue dose using the DDS, a few considerations need to be 
noted. First to point out is that the average dose in the shells (or rinds) was used in our analysis. 
Therefore, it ignored the anisotropic dependence in the relationship. However, in contrast to 
Dose Volume Histogram (DVH) which completely ignores the spatial information, this simple 
analysis still retains the spatial information along the radial direction, and can provide overall 
information about the dose distribution outside the PTV.  But one shall keep in mind that for two 
different plans, even when the average dose within a rind for a plan is higher than that for 
another plan, point doses inside the rind can behave differently for those two plans. Secondly, 
although our results showed that prescription IDLs lower than 90% led to faster dose drop-off in 
the normal tissue near the target and hence better OAR sparing, there is one possible exception. 
When the PTV overlaps with an OAR, changing prescription IDL from a higher IDL to a lower 
one could increase the maximum dose to the OAR. This is because with a lower prescription 
IDL, the dose heterogeneity inside the PTV increases and therefore the portion of the OAR that 
is inside the PTV may likely get higher dose. Thus one needs to be careful to change the 
prescription IDL when the PTV overlaps with an OAR and the maximum dose of the OAR is a 
constraint.  For example, for Patient 5 in our study, part of the brainstem is within the PTV. It 
was found that although the mean dose in the brainstem was the largest for the 90% IDL plan, 
following the trend discovered by our DDS study, the maximum dose on the other hand was the 
lowest compared to that in all other plans prescribed to lower IDLs.  
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       The plans with 60%-70% prescription IDLs achieved the highest (optimal) DDS for all 
patients. Whilst this result indicates an advantageous normal tissue sparing in the medium-to-
high dose region outside the PTV at such prescription IDLs, a few other considerations also need 
to be noted. Firstly and most importantly, it is well known that the probability of necrosis is 
higher with higher dose. As has been studied in Ref. 18, when V10 Gy >10.5 cc or V12 Gy >7.9 cc 
for normal brain tissue, hypofractionated rather than single fraction treatment should be 
considered to minimize the risk of brain radionecrosis. Despite the small amount of normal brain 
tissue contained in the SRS PTV, the higher probability of radionecrosis needs to be considered 
when choosing lower prescription IDLs, as the hot spots within the PTV would be considerably 
hotter than when a high prescription IDL is chosen instead. This potential tradeoff shall always 
be kept in mind when determining an appropriate prescription IDL. Secondly, as can be seen 
from the more spread-out lower isodose lines for the 50% IDL plan in Fig. 3, because a plan with 
a lower prescription IDL requires higher MUs than a higher IDL plan, the integral dose may be 
higher which may lead to a broader low dose spillage due to MLC and machine leakage, in 
addition to the higher absolute dose and higher dose heterogeneity inside the target. Although as 
we chose to focus in the current study, the high dose region is much more critical than the low 
dose region in SRS cases.  Lastly, the intention of this work is not to propose a practice pattern 
change to favor lower prescription IDLs in brain SRS based on our findings. Rather, the goal is 
to demonstrate the normal tissue dose effect of varying prescription IDLs and to explore its 
physical reasons. This way a physician could weigh all possible advantages and disadvantages to 
make an educated decision when choosing what IDL to prescribe for a specific case. 
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      Our analysis shows general trends of dose distribution outside the PTV as the dose drops 
radially. Eq. (1) is a fitting function which describes the dose distribution outside the PTV for the 
whole imaged anatomy. This radial coordinate dependence is usually ignored in the previous 
measures. Therefore, the DDS can be used as a complementary measure to the previous 
measures.  Previous measures such as maximum dose and %50V  are measures of special cases 
such as at a particular dose level, therefore could not provide the global behavior as provided in 
Eq. (1). Of course these measures can always be used in conjunction with our new measure to 
confirm the findings.  For the 40 plans in our study, we also calculated %50V and compared 
among different prescription IDLs.  The results are listed in Table 3. It is clear that the same 
conclusion was reached based on %50V  as based on our proposed DDS, that the optimal sparing 
as indicated by the lowest %50V  was achieved by 70% or 60% IDL plans. Yet we need to point 
out again, even though the same conclusion could be drawn from both measures in this study, 
whilst this selection of the dose level in %50V  is arbitrary and local,   Eq. 1 is a global fitting and 
the DDS extracted from it therefore provides a quantitative measure of a much broader dose 
range. 
 
V. CONCLUSIONS 
      A double exponential decay function was proposed to fit the dose distribution outside the 
PTV, from which the decay coefficient corresponding to the dose drop-off in the medium-to-high 
dose region was named the DDS. This new variable as an indication for normal tissue sparing 
was used to evaluate brain SRS plans planned with the prescription IDL from 50% to 90%. The 
DDS was found to increase with decreasing prescription IDLs and reach a plateau at 70% or 60% 
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IDL. DDS was also found to be target size dependent, smaller with larger PTV volumes. Both 
discovered effects can be explained by the corresponding beam profiles.  .  
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Table Captions:
 
 
Table 1:  Patient characteristics of all 8 patients. 
 
 
 
Patient Index Disease Location PTV volume (cc) 
1 Pituitary Pituitary 16.48 
2 Metastasis Right cerebellar 12.23 
3 Meningioma Anterior left 
parafalcine 
4.37 
4 Pituitary Pituitary 3.64 
5 Metastasis Right side of the pons 
(Brainstem) 
1.68 
6 Metastasis Right frontal lobe 1.05 
7 Acoustic neuroma Left internal auditory 
canal 
0.56 
8 Metastasis Right parietal lobe 
 
0.37 
 
 
 
 
Table 2:   The plan conformity indexes, all fitting parameters from Equation 1, and the total 
numbers of MUs for the SRS plans with 90%-50% prescription IDLs for an example patient 
(Patient 2). For this patient, the plan with 70% IDL achieved both the greatest DDS (b1), and the 
greatest b2, the smaller exponential decay coefficient characterising the dose drop-off in the low 
dose region. 
IDL 90% 80% 70% 60% 50% 
CI 1.230 1.230 1.230 1.221 1.230 
a1 15.720 11.000 10.181 9.940 9.760 
b1 0.136 0.239 0.280 0.276 0.260 
a2 3.506 8.248 9.032 9.437 9.315 
b2 0.0371 0.0620 0.0651 0.0648 0.0634 
Total MU 2465 2792 3200 3755 4531 
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Table 3: The %50V (cm
3
) calculated from the different IDL plans for all Patients.  
 
 
 
IDL 90% 80% 70% 60% 50% 
Patient 1 25.088 24.896 24.448 25.536 33.856 
Patient 2 26.752 20.160 19.392 20.480 22.400 
Patient 3 16.640 13.248 10.880 10.240 11.392 
Patient 4 13.952   8.256   7.360   7.232  7.238 
Patient 5  5.888   4.244    3.392   4.480  3.904 
Patient 6 4.416  2.816  2.624   2.240  2.560 
Patient 7 3.264 2.752 1.984 1.856  1.920 
Patient 8 2.112 1.280 1.216 1.152  1.216 
 
 
 
 
 
Figure Captions: 
 
 
Figure 1:   The zoomed-in axial view of one example patient (Patient 4) showing multiple 
concentric 1mm-thick rind structures generated from the PTV surface. Although only a few rind 
structures are shown in the figure to avoid crowdedness, rind structures were generated layer-by-
layer till they reached the closest head surface for each plan. The average dose in each rind was 
calculated to study the normal tissue dose.  
 
Figure 2:   One example patient plan (Patient 4 at 80% prescription IDL) showing the average 
dose in each rind structure as a function of the distance from the surface of the PTV. The fitted 
values of Eq. (1) were ][43.181 Gya  , ][218.42 Gya  , ]/1[2477.01 mmb  and
]/1[04334.02 mmb  . 
 
Figure 3:   Dose distribution outside PTV for an example patient (Patient 2) for plans with the 
prescription IDL at 90%, 80% 70% (top row from left to right), 60%, and 50%. The plotted 
isodose lines are 20 Gy, 18 Gy, 16 Gy, 14 Gy, 12 Gy, 10 Gy, 6 Gy and 3 Gy from inside to 
outside of the PTV. 
  
Figure 4:  The dose distribution outside the PTV, calculated from the average doses in the rind 
structures, as a function of the distance from the PTV surface for the 5 plans shown in Figure 3 
(Patient 2).  
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Figure 5:   A plot of the DDS vs. the corresponding prescription IDL for all patients, obtained 
from all 40 plans.  
 
Figure 6:   The beam profiles for MLC- defined square fields with various sizes, generated from 
iPlan based on beam models for an SAD (=100 cm) setup at 5cm depth. The plotted field sizes 
are 6mm×6mm, 12mm×12mm, 18mm×18mm, 30mm×30mm, 42mm×42mm and 52mm×52mm. 
 
Figure 7:   The absolute gradients for the beam profiles shown in Figure 5, calculated using the 
first-order derivatives. The corresponding MLC defined square field sizes are 6 mm×6 mm, 12 
mm×12 mm, 18 mm×18 mm, 30 mm×30 mm, 42 mm×42 mm, and 52 mm×52 mm. 
 
Figure 8:  The DDS trend with the PTV diameter, obtained from the phantom study on a 
simulated spherical target.  The spherical target in each simulated case had a diameter of 4.90, 
4.05, 3.20, 2.30, 1.20 cm, respectively.  The centroid location of the varying-sized targets was 
kept the same and the prescription IDL was fixed at 80%.   
 
Figure 9:   The maximum DDS as a function of the PTV volume for all 8 patients. For each 
patient, the maximum DDS value was chosen, regardless of the prescription IDL the value was 
achieved with. 
 
Figure 10:   The gradients of the beam profile calculated as the first-order derivatives at 50%, 
60%, 70%, 80% and 90% of the central axis dose values, for MLC defined square fields with 
varying field sizes ranging from 6mmx6mm to 52mmx52mm. The SAD and depth of 
measurement were the same as those in Figure 6 and Figure 7. 
 
Figure 11:   Percent depth dose (PDD) as a function of depth for different square field sizes. The 
field sizes as well as the 95 cm SSD were the same as those in Figure 6, Figure 7, and Figure 10.  
 
Figure 12:   The absolute value of the PDD gradient (the first-order derivative) as a function of 
depth for varying square field sizes. The gradients were calculated from the corresponding PDD 
curves shown in Figure 11. 
 
 
 
 
 
 
 
 
 
  
24 
 
 
 
 
 
                  Fig.1 
 
  
25 
 
 
 
                                Fig. 2 
 
 
 
  
26 
 
 
                                              Fig.3  
 
 
 
                                                            Fig. 4 
  
27 
 
 
 
                                                    Fig.5  
 
 
 
 
 
 
 
 
 
  
28 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
                                                                   Fig. 6 
 
  
29 
 
 
 
 
                                   Fig.7 
 
  
30 
 
 
 
                                                                 Fig.8 
 
 
 
 
 
 
 
 
 
  
31 
 
 
 
 
 
 
                                                Fig.9 
 
 
 
 
 
 
 
 
  
32 
 
 
 
 
 
 
 
                                                Fig.10 
 
 
 
 
 
  
33 
 
 
 
 
 
 
 
 
 
 
                                                Fig. 11 
 
 
  
34 
 
 
 
 
 
 
 
 
 
 
                                                Fig. 12 
 
